Zhao showed that loss of Smo slowed the renewal of hematopoietic stem cells, reducing the transformation of CML cells [45], while Dierks showed that pharmacological inhibition of Smo in CML patients could help to reduce the spread of imatinib-resistant LSCs during treatment [46]. This evidence concerns the gene SMO and chronic myelogenous leukemia, BCR-ABL1 positive.